The Pharmagellan Guide to Biotech Forecasting and Valuation
Vi har samlet 2 aktuelle varer med samme produktnavn hos Saxo DK på én side.
Denne side samler varer efter forhandler og produktnavn. Det betyder ikke nødvendigvis, at varerne er officielle varianter af samme produkt.
Muligheder hos forhandleren
Vi kan ikke med sikkerhed afgøre, om varerne er varianter eller separate produkter. Sammenlign detaljerne før du går videre.
| Produkt | Varenr. | Pris | Handling |
|---|---|---|---|
| The Pharmagellan Guide to Biotech Forecasting and Valuation | 9780998407500 | 1.044,95 kr | Til butik |
| The Pharmagellan Guide to Biotech Forecasting and Valuation | 9780998407500 | 1.054,95 kr | Til butik |
Produktdetaljer
The Pharmagellan Guide to Biotech Forecasting and Valuation
1.044,95 kr
Til butik- Varenr.:
- 9780998407500
If you're a biotech executive, investor, deal maker, entrepreneur, or adviser--or aspire to be one--then you need to know how to build and analyze forecasts and valuation models of R&D-stage drugs. THE PHARMAGELLAN GUIDE TO BIOTECH FORECASTING AND VALUATION is a comprehensive, thoroughly referenced handbook to creating and interpreting financial models for early-stage biopharma assets and companies. - Vetted benchmarks for key drivers of income, expenses, and valuation. - Proprietary analyses by Pharmagellan's experienced consulting team. - More than 150 current references from peer-reviewed research, industry white papers, and SEC filings. Whether you're making investment decisions, pitching to potential partners or funders, or assessing your own R&D program, this is the one-stop guide you need by your side.
Læs mere hos Saxo DKThe Pharmagellan Guide to Biotech Forecasting and Valuation
1.054,95 kr
Til butik- Varenr.:
- 9780998407500
If you're a biotech executive, investor, deal maker, entrepreneur, or adviser--or aspire to be one--then you need to know how to build and analyze forecasts and valuation models of R&D-stage drugs. THE PHARMAGELLAN GUIDE TO BIOTECH FORECASTING AND VALUATION is a comprehensive, thoroughly referenced handbook to creating and interpreting financial models for early-stage biopharma assets and companies. - Vetted benchmarks for key drivers of income, expenses, and valuation. - Proprietary analyses by Pharmagellan's experienced consulting team. - More than 150 current references from peer-reviewed research, industry white papers, and SEC filings. Whether you're making investment decisions, pitching to potential partners or funders, or assessing your own R&D program, this is the one-stop guide you need by your side.
Læs mere hos Saxo DKOplysningerne kommer fra Saxo DKs aktuelle produktdata.